This is a single-center, retrospective cohort review that included patients aged 18 years or greater with a diagnosis of AML that received azacitidine or decitabine with or without VEN between June 1, 2017 and December 5, 2019 at The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital. To be eligible for inclusion in the efficacy analysis, patients had to receive either 28 days of VEN or reach cycle 2, day 1 of azacitidine or decitabine. To be eligible for inclusion in the safety analysis, patients had to receive at least one dose of either azacitidine or decitabine and VEN, if applicable. Protected populations including pregnant or imprisoned patients, and patients enrolled on a clinical trial were excluded. This study protocol was approved by the Institutional Review Board. This study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration.
Protocol detail
Azacitidine, Decitabine, and Venetoclax in AML
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : The Ohio State University
Top 5 similar protocols
Variable analysis
independent variables
- Treatment with azacitidine or decitabine with or without VEN
- Efficacy outcomes (not explicitly mentioned)
- Safety outcomes (not explicitly mentioned)
- Patients aged 18 years or greater with a diagnosis of AML
- Patients receiving at least one dose of either azacitidine or decitabine and VEN, if applicable
- Exclusion of protected populations including pregnant or imprisoned patients, and patients enrolled on a clinical trial
- No positive or negative controls explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!